

April 08, 2019

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub.: Intimation with respect to allotment of unrated, unlisted, unlisted, redeemable non-convertible debentures

Re: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is in continuation to our letter dated February 26, 2019 intimating that the Board of Directors had in its meeting held on that day, approved issuance of listed/unlisted, secured/unsecured redeemable Non-Convertible Debentures, on private placement basis upto Rs.864 Crore in one or more series/tranches.

We would now like to inform you that the Executive Committee of the Board of Directors of the Company had, in its meeting held on April 08, 2019, approved the allotment of 74,300 unrated, unlisted, redeemable, non-convertible debentures (NCDs), having the face value of Rs.1,00,000/- (Rupees One Lakh Only) each, aggregating to Rs.743 Crore under Series 1A, Series 1B and Series 2 NCDs. The details of the said allotment are mentioned in **Annexure-A**.


This is for your kind information and record please.

Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

for **Panacea Biotec Ltd.**


Vinod Goel
Group CFO and Head Legal
& Company Secretary



Encl. As Above

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070


Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

Annexure-A

S. No.	Particulars	Description																
1.	Type of securities proposed to be issued	Non-Convertible Debentures																
2.	Type of issuance	Private Placement																
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Private Placement by issuing 74,300 (Seventy Four Thousand Three Hundred Only) unrated, unlisted, secured Non-Convertible Debentures ("NCD") of Rs.1,00,000 each ("Debentures Issue Price"), in compliance with the provisions of Companies Act, 2013 and the rules made thereunder.																
4.	Additional information in case of issuance of debt securities																	
i.	Size of the issue	Rs.743,00,00,000																
ii.	Whether proposed to be listed? If yes, name of the stock exchange(s);	The said NCDs are not proposed to be listed																
iii.	Tenure of the instrument (with date of allotment and date of maturity)	<table border="1"> <thead> <tr> <th>NCD Series</th> <th>Date of Allotment</th> <th>Date of Maturity</th> <th>Tenure</th> </tr> </thead> <tbody> <tr> <td>1A</td> <td>08.04.2019</td> <td>08.04.2020</td> <td>12 months and 1 Business Day</td> </tr> <tr> <td>1B</td> <td>08.04.2019</td> <td>07.04.2024</td> <td>60 months</td> </tr> <tr> <td>2</td> <td>08.04.2019</td> <td>17.10.2020</td> <td>18 months & 10 days</td> </tr> </tbody> </table>	NCD Series	Date of Allotment	Date of Maturity	Tenure	1A	08.04.2019	08.04.2020	12 months and 1 Business Day	1B	08.04.2019	07.04.2024	60 months	2	08.04.2019	17.10.2020	18 months & 10 days
NCD Series	Date of Allotment	Date of Maturity	Tenure															
1A	08.04.2019	08.04.2020	12 months and 1 Business Day															
1B	08.04.2019	07.04.2024	60 months															
2	08.04.2019	17.10.2020	18 months & 10 days															
iv.	Coupon Rate / Schedule of Payment of Coupon / interest and principal	<p>20% IRR will be paid on the NCDs (Cash Coupon + Redemption Premium)</p> <p>Schedule of Principal Payment</p> <table border="1"> <thead> <tr> <th>NCD Series</th> <th>Record date for Principal Payment</th> <th>Tenure</th> </tr> </thead> <tbody> <tr> <td>IA</td> <td>12 months and 1 Business Day</td> <td>08.04.2020</td> </tr> <tr> <td>IB</td> <td>60 months</td> <td>07.04.2024</td> </tr> <tr> <td>2</td> <td>18 months & 10 days</td> <td>17.10.2020</td> </tr> </tbody> </table>	NCD Series	Record date for Principal Payment	Tenure	IA	12 months and 1 Business Day	08.04.2020	IB	60 months	07.04.2024	2	18 months & 10 days	17.10.2020				
NCD Series	Record date for Principal Payment	Tenure																
IA	12 months and 1 Business Day	08.04.2020																
IB	60 months	07.04.2024																
2	18 months & 10 days	17.10.2020																
v.	Charge/ Security, if any created over the assets	<p>The security package will include (among others):</p> <p>i) Exclusive first charge on all fixed and current assets, and pledge on at least 64.94% of the equity share capital of the Company (in two tranches, viz. 51.04% upfront and remaining 13.90% post demerger of Radhika Heights Limited) held by Promoters and Promotees</p>																



		<p>Group.</p> <p>ii) Personal Guarantees provided by Dr. Rajesh Jain, Mr. Sandeep Jain and Mr. Ankesh Jain</p> <p>iii) Corporate guarantee provided by the Company's Wholly-owned Subsidiary Panacea Biotec Pharma Limited</p>
vi.	Special rights / interest / privileges attached to the instrument and changes thereof;	NA
vii.	Delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal	NA
viii.	Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and / or the assets along with its comments thereon, if any	NA
ix.	Details of redemption of preference shares indicating the manner of redemption (whether out of profits or out of fresh issue) and debentures	NA

